Researchers from Nordic Bioscience A/S and Keybioscience AG have published data from a study that aimed to assess the impact of treatment sequencing or combination therapy with the novel long-acting dual amylin and calcitonin receptor agonist (DACRA) KBP-336 and the glucagon-like peptide-1 (GLP-1) analogue semaglutide for the treatment of obesity and associated co-morbidities.
Researchers from Kunming University of Science and Technology and affiliated organizations presented discovery and preclinical evaluation of a novel salinomycin derivative, SAL-98, as a potential therapeutic candidate for the treatment of cancer.
Novaccess Global Inc. has signed a letter of intent and formed a partnership with BCN Biosciences LLC to expand its immunotherapy platform. Utilizing BCN’s small-molecule drug BCN-057, Novaccess Global has begun the development of a fourth generation of its novel brain tumor immunotherapy TLR-AD-1, targeting glioblastoma.
Researchers from Hepagene Therapeutics Inc. have disclosed preclinical data for the novel FXR agonist HPG-1860, which is being developed for the treatment of nonalcoholic steatohepatitis (NASH).
Colonization of the stomach by the bacterium Helicobacter pylori can cause gastric cancer by secreting the CagA oncoprotein. Now, a Japanese laboratory has discovered that CagA disrupted Wnt/PCP signaling and altered the polarity in which the squamous cells of the developing gastric epithelium are arranged, causing the hyperproliferation of the stem cells.
Researchers at the Salk Institute for Biological Studies have shown a possible beneficial role for muscle wasting in mice infected with Trypanosoma brucei, a parasite that causes sleeping sickness in humans. The team assessed the impact of both fat and muscle wasting on survival of mice with T. brucei infection. They found that while fat wasting appeared to have no impact on survival, mice that were unable to undergo muscle wasting died more quickly from the infection than those that experienced muscle loss.
The identification of new targets in diseases of the central nervous system (CNS) such as Alzheimer’s and Parkinson’s – conditions which continue to have significant unmet needs – has taken a small step forward as one company, Violet Therapeutics Inc., plans to put $10.6 million in seed funding toward building out a pipeline based on technologies that elucidate the way cells interact amongst one another.
Astellas Pharma Inc. has divulged substituted quinolone derivates acting as acetylcholine receptor cluster inducers reported to be useful for the treatment of neuromuscular disorders.
RSS
